Search clinical trials for: Cetuximab

Total 3058 results

UNICANCER

Terminated

Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss (COPAN-ORL06)

Carcinoma, Squamous Cell of Head and Neck

France
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Merck Sharp & Dohme LLC

Unknown

Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance (I-Tackle)

Skin Neoplasm

Italy
Martin Schuler, Prof. Dr. med.

Completed

Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer (CEBIFOX)

Metastatic Colorectal Cancer

Germany
Merck KGaA, Darmstadt, Germany

Completed

Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC) (OPUS)

Neoplasm Metastasis | Colorectal Cancer

France, Italy, Poland, Russian Federation, Spain, Germany, Austria, Belgium, Israel, Romania, Greece, Ukraine, Portugal
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Completed

Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer

Endometrial Cancer

United States
University of Texas Southwestern Medical Center

Completed

Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer

Head and Neck Cancer

United States
Alliance for Clinical Trials in Oncology
Bristol-Myers Squibb; National Cancer Institute (NCI); Eli Lilly and Company

Completed

Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer

Lung Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer

Esophageal Cancer

United States
AVEO Pharmaceuticals, Inc.

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma

United States, Australia, Canada, United Kingdom
Astellas Pharma Inc

Recruiting

A Study of ASP3082 in Adults With Previously Treated Solid Tumors

Solid Tumor

United States, Japan
Pierre Fabre Medicament
Pfizer; Merck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. Ltd

Completed

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC)

BRAF V600E-mutant Metastatic Colorectal Cancer

France, Italy, United States, Spain, United Kingdom, Belgium, Austria, Japan, Netherlands
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell Cancer | Recurrent Head and Neck Squamous Cell Cancer | Metastatic Head and Neck Squamous Cell Cancer

United States
NKGen Biotech, Inc.

Withdrawn

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Sarcoma | Cervical Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | EGF-R Positive Non-Small... and other conditions
GeneScience Pharmaceuticals Co., Ltd.
Shanghai East Hospital

Unknown

Pharmacokinetics and Tolerancebility Studies of Gentuximab Injection in the Treatment ofPatients With Late Recurrence of Metastatic Solid Tumors in China

Solid Tumor

China
Grupo Español de Tratamiento de Tumores de Cabeza...
Bristol-Myers Squibb; Apices Soluciones S.L.

Active, not recruiting

Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) (NIVOTAX)

Recurrent Head and Neck Squamous Cell Carcinoma | Head and Neck Cancer Stage IV

Spain
City of Hope Medical Center
National Cancer Institute (NCI)

Terminated

Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment

Colorectal Cancer

United States
Technical University of Munich

Unknown

Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer

Esophageal Cancer

Germany
Centre Hospitalier Universitaire Vaudois

Unknown

Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer

Colorectal Cancer

Switzerland
National Cancer Institute (NCI)

Completed

Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | CD20 Positive

United States
Swiss Group for Clinical Cancer Research

Completed

Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery

Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

Switzerland, France, Austria, Germany, Hungary
Southwest Oncology Group
National Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia...

Completed

S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer

Pancreatic Cancer

Canada, United States
University of Alabama at Birmingham
National Cancer Institute (NCI)

Withdrawn

Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas

Pancreatic Cancer
Association pour la Recherche sur le Temps Biologique...
Pfizer; Merck Serono International SA; Gustave Roussy, Cancer Campus, Grand Paris and other collaborators

Unknown

Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy (OPTILIV)

Metastatic Colorectal Cancer | Liver Metastases | Hepatic Lesions

France, Italy, Belgium, Portugal
Leiden University Medical Center

Unknown

Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer

Colorectal Cancer

Netherlands
Sandoz
Hexal AG

Completed

GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera® (ASSIST-RT)

Rheumatoid Arthritis

United States, Germany, Poland, Hungary
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

Lymphoma

United States
Lymphoma Study Association
Amgen

Terminated

ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma

Diffuse Large Cell Lymphoma

France, Belgium, Switzerland
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

Lymphoma

United States, Canada
Dong-A University Hospital

Completed

Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)

Lymphoma

Korea, Republic of
University of California, San Francisco

Completed

Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma

Lymphoma | Brain and Central Nervous System Tumors
Assistance Publique - Hôpitaux de Paris

Completed

Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura (PTTritux)

Thrombotic Thrombocytopenic Purpura

France
Neufeld, Ellis J, MD, PhD
Genentech, Inc.; Biogen; Glaser Pediatric Research Network; Terrana ITP Research...

Completed

Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Immune Thrombocytopenic Purpura (ITP) | Idiopathic Thrombocytopenic Purpura (ITP)

United States
National Pediatric Neuroinflammation Organization...
Genentech, Inc.

Completed

Effectiveness of Rituximab in Pediatric OMS Patients.

Ataxia | Myoclonus | Opsoclonus-myoclonus Syndrome | Opsoclonus

United States
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

LMBA02 Protocol for Patients With a Burkitt Lymphoma

Burkitt Lymphoma

France
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

Colorectal Cancer | Colorectal Cancer Stage IV | Stage IV Colorectal Cancer Positive for BRAF V600E Mutation

United States
Presage Biosciences
Takeda

Completed

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

Head and Neck Cancer

United States
University of Chicago
National Cancer Institute (NCI)

Completed

PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
AbbVie (prior sponsor, Abbott)

Completed

Study of ABT-700 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors
University of Tennessee Cancer Institute
National Comprehensive Cancer Network

Terminated

Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

United States
National Cancer Institute (NCI)

Active, not recruiting

Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IV Colon Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Unresectable Colon Adenocarcinoma | Unresectable Rectal Adenocarcinoma

United States, Puerto Rico
University of Chicago
Verastem, Inc.

Recruiting

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Colorectal Cancer | Colorectal Cancer Metastatic | Colorectal Adenocarcinoma | Advanced Colorectal Carcinoma | Advanced Colorectal Adenocarcinoma

United States
Innate Pharma
AstraZeneca

Completed

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Neoplasms

United States, France
Trans Tasman Radiation Oncology Group

Completed

Chemoradiation Treatment for Head and Neck Cancer

Head and Neck Cancer

Australia
Stanford University

Completed

Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy

Lymphoma

United States
University Hospital Erlangen

Completed

Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia

Lymphoma | Leukemia

Germany, Switzerland
Celltrion

Completed

Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis (Triad RA)

Rheumatoid Arthritis

Korea, Republic of
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma

Lymphoma

United States
Swiss Group for Clinical Cancer Research

Completed

Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy

Leukemia

Switzerland

Search clinical trials for: Cetuximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations